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Introduction: In patients with epidermal growth factor receptor 
(EGFR)-mutant or KRAS-mutant lung adenocarcinomas, the prog-
nostic impact of a concurrent PIK3CA mutation remains unclear. 
Although preclinical data suggest that sensitivity to EGFR tyrosine 
kinase inhibition (TKI) is decreased in EGFR-mutant lung cancers 
also harboring a PIK3CA mutation, this interaction has not been 
explored clinically.
Methods: Patients with lung adenocarcinomas harboring a PIK3CA 
mutation concurrent with a separate driver mutation were identi-
ﬁed through mutational hotspot testing, multiplex sizing assays, and 
fluorescence in situ hybridization. Overall survival and outcomes 
with EGFR TKI monotherapy (EGFR-mutant) were estimated using 
Kaplan–Meier methods and compared between double-mutant 
(EGFR-mutant or KRAS-mutant, concurrent PIK3CA-mutant) and 
single-mutant patients (EGFR-mutant or KRAS-mutant, PIK3CA 
wild-type) using log-rank tests.
Results: In EGFR-mutant and KRAS-mutant lung cancers, a con-
current PIK3CA mutation was associated with a decrease in median 
overall survival: 18 versus 33 months (EGFR double mutant, n = 10 
versus single mutant, n = 43, p = 0.006), and 9 versus 16 months 
(KRAS double mutant, n = 16 versus single mutant, n = 47, p = 0.020). 
In EGFR-mutant lung cancers, a concurrent PIK3CA mutation did 
not impact beneﬁt from EGFR TKI monotherapy. Single versus dou-
ble mutant: objective response rate, 83% (n = 29) versus 62% (n = 6, 
p = 0.80); median time to progression, 11 (n = 29) versus 8 months 
(n = 6, p = 0.84); and median duration of TKI therapy, 15 (n = 32) 
versus 15 months (n = 10, p = 0.65).
Conclusion: A concurrent PIK3CA mutation is a poor prognostic 
factor in patients with advanced EGFR-mutant or KRAS-mutant lung 
adenocarcinomas. There was no evidence that clinical beneﬁt from 
EGFR TKI monotherapy is affected by a concurrent PIK3CA muta-
tion in EGFR-mutant lung cancers.
Key Words: PIK3CA mutation, EGFR-mutant lung adenocarcino-
mas, Tyrosine kinase inhibitors.
(J Thorac Oncol. 2015;10: 1713–1719)
PIK3CA mutations are found in approximately 7% of patients with lung adenocarcinomas.1 These mutations 
usually occur in hotspots in exons 9 and 20, corresponding to 
the helical and kinase domains of p110α, the catalytic subunit 
of the PI3K enzyme. Mutations in these locations can result 
in constitutive activation of PI3K activity, phosphorylation 
of AKT, and downstream activation of mTORC1, which are 
essential for cell survival and proliferation.2,3
In contrast to the mutual exclusivity of many onco-
genic driver mutations in lung cancers, the co-occurrence of 
PIK3CA mutations with mutations in other oncogenic driver 
genes in lung adenocarcinomas is well described.4–6 The Lung 
Cancer Mutation Consortium identiﬁed a PIK3CA mutation 
through comprehensive molecular proﬁling in almost half 
of all lung cancers where a genomic alteration in more than 
one oncogene was found.7 Previous series have described the 
characteristics of PIK3CA-mutant lung cancers as a subgroup, 
but the role that PIK3CA mutations play as modiﬁers of clini-
cal outcomes in epidermal growth factor receptor (EGFR)-
mutant and KRAS-mutant lung cancers has not previously 
been deﬁned.
From a therapeutic standpoint, an important question is 
whether or not PIK3CA mutations affect response to EGFR 
tyrosine kinase inhibitor (TKI) therapy in EGFR-mutant lung 
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cancers. In vitro EGFR TKI sensitivity in EGFR-mutant lung 
cancer cell lines has been correlated with downregulation of 
the PI3K pathway.8 The introduction of the activating PIK3CA 
E545K mutation into a geﬁtinib-sensitive EGFR-mutant lung 
cancer cell line (HCC827, EGFR exon 19 deletion) through 
retroviral infection, for example, results in increased resis-
tance to geﬁtinib and protection from geﬁtinib-mediated 
apoptosis.9 These preclinical data suggest that activation of 
the PI3K pathway can blunt the response to TKI therapy, but 
clinical series have not previously been reported.
We set out to determine the prognostic impact of PIK3CA 
mutations in patients whose lung cancers harbor a mutation in 
a second driver, particularly EGFR and KRAS, as these are the 
most common oncogenes in lung cancer.4,10 In addition, we 
compared EGFR TKI therapy outcomes in patients with con-
current EGFR-mutant and PIK3CA-mutant lung cancers with 
that of patients with EGFR-mutant and PIK3CA wild-type 
lung cancers to elucidate the impact of PIK3CA mutations 
on response rate, overall survival (OS), time to progression 
(TTP), and duration of TKI therapy.
PATIENTS AND METHODS
Patient Selection
Patients with newly diagnosed lung adenocarci-
nomas who were evaluated at Memorial Sloan Kettering 
Cancer Center between January 2009 and July 2013 were 
retrospectively identiﬁed as part of an institutional review 
board-approved study. Pathologic conﬁrmation of lung ade-
nocarcinoma histology was performed by the Department 
of Pathology. Patients who received systemic therapy before 
molecular diagnostic testing were excluded.
Targeted molecular proﬁling of tumor tissue was per-
formed through an institutional algorithm under the Lung 
Cancer Molecular Analysis Project in the following order: 
(1) multiplex sizing assays for insertions and deletions in 
EGFR and ERBB2, (2) mutational hotspot testing by a mass 
spectrometry-based nucleic acid assay on the Sequenom (San 
Diego, CA) platform for 91 mutations in eight genes (EGFR, 
HER2, KRAS, NRAS, BRAF, MAP2K1, PIK3CA, and AKT1), 
and (3) break apart fluorescence in situ hybridization tests for 
recurrent gene rearrangements involving ALK.
We identiﬁed subjects whose tumors harbored a 
PIK3CA mutation concurrent with one of the following 
genomic alterations: mutations in EGFR, KRAS, ERBB2, 
NRAS, BRAF, MAP2K1, and AKT1 and rearrangements 
involving ALK. These tumors are hereafter referred to as 
double-mutant (double-Mt). Three control groups of single-
mutant (single-Mt) patients were also identiﬁed: (1) single 
EGFR-Mt (EGFR-mutant, PIK3CA wild type), (2) single 
KRAS-Mt (KRAS-mutant, PIK3CA wild type), and (3) single 
PIK3CA-mutant (PIK3CA-mutant, EGFR and KRAS wild 
type). A review of clinicopathologic and molecular features 
was conducted.
This study includes 19 patients from our previously 
published series of PIK3CA-mutant lung cancers4 (12 double-
Mt and 7 PIK3CA single-Mt), as this article did not examine 
prognosis in EGFR-mutant and KRAS-mutant lung cancer 
subsets or response to EGFR TKI therapy in EGFR-mutant 
lung cancers.
Response Evaluation
Outcomes with EGFR TKI monotherapy were deter-
mined for all patients with a sensitizing EGFR mutation, 
including patients with EGFR single-Mt and EGFR double-
Mt (concurrent EGFR and PIK3CA mutations) lung cancers. 
Radiographic review of all available imaging studies at base-
line and on serial follow-up on therapy was performed by a 
thoracic radiologist (A.P.).
Patients were evaluable for radiographic response if 
they had both baseline imaging and at least one repeat evalua-
tion after continuous EGFR TKI monotherapy. Best response 
to EGFR TKI monotherapy was categorized as a complete 
response (CR), partial response, stable disease, or progression 
of disease based on the Response Evaluation Criteria In Solid 
Tumors (RECIST) version 1.1.
Statistics
OS and outcomes with EGFR TKI monotherapy includ-
ing TTP and duration of therapy were calculated using the 
Kaplan–Meier method. OS was calculated from the date of 
diagnosis of metastatic disease until death. Patients who did 
not die during the study time were censored at the date of 
last available follow-up. TTP was calculated from the date 
of initiation of EGFR TKI monotherapy until radiographic 
progression through RECIST v1.1 on therapy. Patients who 
did not progress were censored at date of last follow-up on 
EGFR TKI.
Duration of therapy was calculated from the date 
of initiation until the last documented visit date on EGFR 
TKI monotherapy. Patients were censored if we did not have 
further follow-up on them beyond this date. Time to best 
response was calculated from the date of initiation of EGFR 
TKI monotherapy until date of best response by RECIST 
v1.1. OS, TTP, time to best response, and duration of ther-
apy were compared between molecularly deﬁned subgroups 
using the log-rank test. Time to best response was com-
pared between single-Mt and double-Mt patients using the 
Wilcoxon rank sum test. Fisher’s exact test was used to ana-
lyze the association between single-Mt or double-Mt tumors 
and best response. All statistical tests were two-sided, and the 
level of signiﬁcance was 5% (p < 0.05). Statistical analyses 
were performed using R (version 3.0.1; R Development Core 
Team) with the “survival” package.
RESULTS
Patients
We identiﬁed 37 patients with oncogene-driven lung 
adenocarcinomas that harbored a concurrent PIK3CA muta-
tion (Table 1). The majority of patients were female (70%, 
n = 26 of 37), with a history of current or former cigarette 
smoking (76%, n = 29 of 37) and stage IIIB/IV disease at 
diagnosis (65%, n = 24 of 37).
PIK3CA mutations were predominantly found in the 
exon 9 helical domain (70%, n = 26 of 37; including E542K, 
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E545K, 3545G, and E545D) and the remainder in the exon 
20 catalytic domain (30%, n = 11 of 37; including H1047R 
and H1047L). Genomic alterations that were concurrently 
identiﬁed with PIK3CA mutations included KRAS mutations 
(n = 22, 59%), EGFR mutations (n = 13, 35%), a BRAF 
V600E mutation (n = 1, 3%), and a MAP2K1 K57N mutation 
(n = 1, 3%).
KRAS was the most common concurrently mutated gene 
in patients with PIK3CA exon 9 mutations (69%, n = 18 of 26), 
whereas EGFR was the most common concurrently mutated 
gene in patients with PIK3CA exon 20 mutations (55%, 
n = 6 of 11). No major differences in mutation type, gender, 
and smoking history were noted between EGFR double-Mt 
and single-Mt, and KRAS double-Mt and single-Mt patients 
(p > 0.05, Supplementary Table 1, Supplemental Digital 
Content, http://links.lww.com/JTO/A895).
Prognostic Impact of Concurrent 
PIK3CA Mutations
In EGFR-mutant lung adenocarcinomas, median OS 
was shorter in patients with metastatic double-Mt than in 
patients with metastatic single-Mt disease: 18.0 months 
(95% conﬁdence interval [CI], 13.9 to not applicable months, 
n = 10) versus 33.3 months (95% CI, 28.2 to NA months, 
p = 0.006,n = 43) (Fig. 1A). Similarly, in KRAS-mutant lung 
adenocarcinomas, median OS was shorter in patients with 
metastatic double-Mt than in patients with metastatic single-
Mt disease: 8.9 months (95% CI, 7.8 to NA months, n = 16) 
versus 16.2 months (95% CI, 10.7–27.5 months, p = 0.020, 
n = 47) (Fig. 1B).
Conversely, in PIK3CA-mutant lung adenocarcinomas, 
the presence of a concurrent EGFR mutation or KRAS muta-
tion did not signiﬁcantly affect median OS compared with 
patients without a concurrent mutation. Median OS was 18.0 
months (95% CI, 13.9 to NA months, n = 10) in PIK3CA 
Mt/EGFR Mt versus 9.1 months in PIK3CA Mt/EGFR wild-
type patients (95% CI, 4.4 to NA months, p = 0.87, n = 16) 
(Fig. 1C). Likewise, median OS was 8.9 months in PIK3CA 
Mt/KRAS Mt (95% CI, 7.8 to NA months, n = 16) compared 
with 9.1 months in PIK3CA Mt/KRAS wild-type patients 
(95% CI, 4.4 to NA months, p = 0.40, n = 16) (Fig. 1D).
Predictive Impact of Concurrent PIK3CA 
Mutations on EGfR TKI Therapy in 
EGFR-Mutant Lung Cancers
No difference in best objective response to EGFR TKI 
monotherapy was noted between patients with EGFR single-
Mt (n = 29) and double-Mt (n = 6) lung adenocarcinomas 
(18 of 29, 62% versus 5 of 6, 83%; p = 0.80). Similarly, there 
was no difference in time to best response: 2.6 months (range, 
0.9–8.3 months) versus 1.9 months (range, 0.7–13.6 months, 
p = 0.65). Receipt of local therapy (radiation or surgery) 
for oligoprogressive disease did not differ between groups 
(p = 0.99). These outcomes are summarized in Table 2.
There was no difference in TTP between EGFR single-Mt 
and double-Mt patients: 11.1 months (95% CI, 7.5–18.4 months) 
versus 7.8 months (95% CI, 7.1 to NA months, p = 0.84). No 
difference in median duration of TKI monotherapy was noted 
(Fig. 2): 14.5 months (95% CI, 12.6 to NA months) versus 14.6 
months (95% CI, 7.1 to NA months, p = 0.65).
Subgroups with EGFR exon 19 deletions and L858R 
mutations were examined separately and did not reveal any 
signiﬁcant differences (p > 0.05) in TTP or duration of TKI 
monotherapy between single-Mt and double-Mt patients.
DISCUSSION
We demonstrate that the presence of a concurrent 
PIK3CA mutation in patients with EGFR-mutant and KRAS-
mutant lung adenocarcinomas confers a distinct natural his-
tory. Median OS was substantially decreased compared with 
patients whose tumors did not harbor PIK3CA mutations. To 
our knowledge, this article represents the largest series of 
oncogene-driven lung cancers with concurrent PIK3CA muta-
tions to date and is the ﬁrst to demonstrate this phenomenon 
within speciﬁc genomic subsets of lung cancers. Although the 
importance of single PIK3CA mutations as lung cancer driv-
ers relative to other established oncogenes remains in ques-
tion, these data argue that tumors with concurrent PIK3CA 
mutations represent a unique subset within EGFR-mutant and 
KRAS-mutant lung cancers.
TABLE 1. The Clinical and Molecular Features of PIK3CA-
Mutant Lung Cancers Harboring a Concurrent Driver 
Oncogene
PIK3CA Double-Mutant Lung Cancers (N = 37)
Agea (yr) 68 (38–89)
Gender
  Male 11 (30%)
  Female 26 (70%)
Smoking history
  Never 9 (24%)
  Former 24 (65%)
  Current 4 (11%)
  Pack years smokeda 31 (0–120)
Stage at diagnosis
  I–IIIA 13 (35%)
  IIIB/IV 24 (65%)
PIK3CA mutation
  Exon 9
   E542K 12 (32%)
   E545K 12 (32%)
   E545G 1 3%)
   E545D 1 (3%)
  Exon 20
   H1047R 6 (16%)
   H1047L 5 (14%)
Concurrent mutation
  KRAS 22 (60%)
  EGFR 13 (35%)
  BRAF 1 (3%)
  MAP2K1 1 (3%)
aMedian (range).
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fIGURE 1. (Continued).
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fIGURE 1. Impact of PIK3CA mutations on overall survival (OS). OS of patients with epidermal growth factor receptor (EGFR) 
single-mutant versus double-mutant lung cancers (A), KRAS single-mutant versus double-mutant lung cancers (B), EGFR double-
mutant versus PIK3CA single-mutant lung cancers (C), and KRAS double-mutant versus PIK3CA single-mutant lung cancers (D).
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The data presented here are consistent with what is 
expected based on the known biological signiﬁcance of 
PIK3CA in lung cancers and its cooperative role in mito-
genic signaling pathways. In a genetically engineered KRAS 
G12D-mutant murine lung cancer model, tumorigenesis was 
reliant on binding of the p110α subunit of PI3K to KRAS.11 
Abrogation of this interaction resulted in a substantial 
reduction in lung tumor formation. In addition, given that 
PIK3CA H1074R was sufﬁcient for the development of lung 
adenocarcinomas in vivo in a separate model,12 this raises the 
question of the impact of a concurrent PIK3CA mutation on 
oncogenesis within KRAS-mutant lung cancers. In BRAF-
mutant lung adenocarcinoma mouse models, the concomitant 
expression of BRAF V600E and PIK3CA H1047R resulted 
in a dramatic increase in tumor burden compared with BRAF 
V600E alone, emphasizing the malignant synergy observed 
with coexisting mutations.13
Importantly, our series also represents the ﬁrst system-
atic evaluation of the predictive value of PIK3CA mutations on 
EGFR TKI therapy in EGFR-mutant lung cancers. Preclinical 
studies have postulated that PIK3CA mutations could abrogate 
the effectiveness of EGFR TKIs as the presence of a PIK3CA 
mutation results in decreased response and diminished apop-
tosis with geﬁtinib in an EGFR-mutant lung cancer model.9 
Furthermore, reestablishing PI3K pathway activity has been 
described as a mechanism of acquired resistance in EGFR-
mutant lung cancers through the acquisition of PIK3CA muta-
tions14 or activation of other receptor tyrosine kinases (e.g., 
MET ampliﬁcation).15 In HER2-positive breast cancer, the 
presence of a PIK3CA mutation has been associated with lower 
pathologic CR rates16 and inferior disease-free survival after 
neoadjuvant HER2-directed therapy.17 However, we found no 
evidence that a concurrent PIK3CA mutation impacts the out-
comes of EGFR TKI therapy, including objective response, 
time to response, TTP, and duration of EGFR TKI therapy in 
patients with EGFR-mutant lung cancers. Although the small 
size of this retrospective study limits deﬁnitive conclusions, 
these data support the conclusion that the decision regarding 
whether to initiate EGFR TKI therapy in the clinic should be 
unaffected by the presence of a concurrent PIK3CA mutation.
Despite the absence of signiﬁcant differences in out-
comes with EGFR TKI monotherapy, several observations 
can be made. Although all double-mutant patients (EGFR-
Mt/PIK3CA-Mt) came off therapy within 2 years, about a 
third of single-mutant patients (EGFR-Mt/PIK3CA wild-type) 
remained on treatment for an additional year. In addition, CRs 
were only noted in single-mutants. This highlights the need 
TABLE 2. Impact of PIK3CA Mutations on EGFR TKI in 
Patients with EGFR-Mutant Lung Cancers





TKI analysis N = 32 N = 10
Duration of therapy
  Median duration,  
  95% CI (mo)
14.5 (12.6 to NA) 14.6 (7.1 to NA) 0.65
   6 mo on therapy 91% 100%
   1 yr on therapy 68% 67%
   2 yr on therapy 34% 0%
   3 yr on therapy 34% 0%
Local therapy for 
oligoprogressive disease 
during therapy
8 (25%) 2 (20%) 0.99
RECIST 1.1 analysis N = 29 N = 6
Best response
  CR 2 (7%) 0 0.80
  PR 16 (55%) 5 (83%)
TTP
  Median TTP,  
  95% CI (months)
11.1 (7.5–18.4) 7.8 (7.1 to NA) 0.84
   6 mo progression free 76% 83%
   1 yr progression free 42% 44%
   2 yr progression free 20% 0%
   3 yr progression free 7% 0%
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; Mt, 
mutation; RECIST, Response Evaluation Criteria In Solid Tumors; CR, complete 
response; PR, partial response; TTP, time to progression.
fIGURE 2. Duration of epidermal growth fac-
tor receptor (EGFR) tyrosine kinase inhibition (TKI) 
therapy for patients with EGFR single versus double-
mutant lung cancers.
1719Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ® • Volume 10, Number 12, December 2015 Prognostic Impact of a Concurrent PIK3CA Mutation
to conﬁrm these data prospectively in ongoing and future tri-
als of EGFR-directed therapies by including comprehensive 
molecular genomic proﬁling.
CONCLUSION
Concurrent PIK3CA mutations are poor prognostic fac-
tors within independent groups of EGFR-mutant and KRAS-
mutant lung adenocarcinomas. There was no evidence that 
clinical outcomes with EGFR TKI monotherapy in EGFR-
mutant lung cancers are affected by PIK3CA status. These 
data illustrate that mutations in PIK3CA can act as biologi-
cally relevant driver oncogenes but do not negate the therapeu-
tic beneﬁts of molecular therapies in patients with concurrent 
targetable oncogenes.
REfERENCES
 1. Cancer Genome Atlas Research Network. Comprehensive molecular pro-
ﬁling of lung adenocarcinoma. Nature 2014;511:543–550.
 2. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. 
Oncogene 2008;27:5486–5496.
 3. Engelman JA. Targeting PI3K signalling in cancer: opportunities, chal-
lenges and limitations. Nat Rev Cancer 2009;9:550–562.
 4. Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other 
oncogene mutations in lung adenocarcinoma-rationale for comprehensive 
mutation proﬁling. Mol Cancer Ther 2012;11:485–491.
 5. Scheffler M, Bos M, Gardizi M, et al. PIK3CA mutations in non-small 
cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and 
incidence of prior malignancies. Oncotarget 2014;6:1315–1326.
 6. Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese 
lung cancer patients. Lung Cancer 2006;54:209–215.
 7. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays 
of oncogenic drivers in lung cancers to select targeted drugs. JAMA 
2014;311:1998–2006.
 8. Engelman JA, Jänne PA, Mermel C, et al. ErbB-3 mediates phosphoinosit-
ide 3-kinase activity in geﬁtinib-sensitive non-small cell lung cancer cell 
lines. Proc Natl Acad Sci U S A 2005;102:3788–3793.
 9. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures 
detection of a biologically signiﬁcant resistance mutation in EGFR-
ampliﬁed lung cancer. J Clin Invest 2006;116:2695–2706.
 10. Wang L, Hu H, Pan Y, et al. PIK3CA mutations frequently coexist 
with EGFR/KRAS mutations in non-small cell lung cancer and sug-
gest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One 
2014;9:e88291.
 11. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 
3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 
2007;129:957–968.
 12. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK 
inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung 
cancers. Nat Med 2008;14:1351–1356.
 13. Trejo CL, Green S, Marsh V, et al. Mutationally activated 
PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung can-
cer progression. Cancer Res 2013;73:6448–6461.
 14. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histo-
logical evolution of lung cancers acquiring resistance to EGFR inhibitors. 
Sci Transl Med 2011;3:75ra26.
 15. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at 
the time of acquired resistance to EGFR-TKI therapy in 155 patients with 
EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240–2247.
 16. Loibl S, von Minckwitz G, Schneeweiss A, et al. PIK3CA mutations 
are associated with lower rates of pathologic complete response to anti-
human epidermal growth factor receptor 2 (her2) therapy in primary 
HER2-overexpressing breast cancer. J Clin Oncol 2014;32:3212–3220.
 17. Cizkova M, Dujaric ME, Lehmann-Che J, et al. Outcome impact of 
PIK3CA mutations in HER2-positive breast cancer patients treated with 
trastuzumab. Br J Cancer 2013;108:1807–1809.
